anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
Antacid compsns. almost free of alkali metal are prepd. by reacting MgCO3 and/or Mg(HCO3)2 with AlCl3 and/or magnesium aluminium hydroxychloride in an aq. medium to ppte. a gel depending on the reactants used, sepg. the gel from the mixt. to give an antacid practically free of alkali metal, the proprotion of the reactants being such that the Mg contained in the gel is only a fraction of that found in such co-gels which may have a MgO/Al2O3 ratio of 2:1, pref. 1:2. Suitable for treating peptic ulcer, dyspepsia etc. in patients with hepatic or cardiac disorders in whomalkali metal excess is undesirable.
Group of standard glycemia control: blood glucose level will be maintained by continuous insulin infusion (see above) within normoglycemia limits (4.4 - 6.1 mmol/l) after patient's admission to ICU after cardiac surgery. During surgery hyperglycemia will not be interfered before it will reach level of 10 mmol/l.
Patients receive rituximab IV on days 1, 8, 15, and 22 and oral beta-glucan once daily on days 1-28 (days 8-28 of course 1). Treatment repeats every 42 days for 4 courses.
PURPOSE:To provide a medial preparation produced by compounding a physiologically active substance into a pressure-sensitive adhesive containing pullulan, applicable to the skin without causing rush of the skin, having excellent retainability, slowly releasing property and skin-permeability of the physiologically active substance and capable of giving an excellent drug. CONSTITUTION:A prescribed amounts of a physiologically active substance is mixed into a pullulan-containing pressure-sensitive adhesive agent, e.g. a pressure-sensitive adhesive agent produced by mixing 5pts.wt. of pullulan with 2-7pts.wt. of a tackifying agent and a plasticizing agent (e.g. glycerol, lecithin, etc.), 3-25pts.wt. of a diluent and a viscosity modifier (e.g. glucose, dextrin, etc.) and 0.03-0.6pts.wt. of a cohesive force improving agent (e.g. CMC, sodium alginate, etc.). When the physiologically active substance is an oil-soluble substance, it can be stably dispersed by compounding the substance in the form of a clathrate compound with cyclodextrin or after encapsulating in microcapsules.
PURPOSE:To obtain a cosmetic pack which can be easily used simply by pasting to the skin, by adding a cosmetic pack material to a substrate capable of forming a thin film and composed of KONJAK (starch of devil's tongue) gel, carrageenan and a hydrolyzed gelatin and subjecting the mixture to heating, cooling, drying and rolling. CONSTITUTION:A substrate for forming a thin film is composed of (A) KONJAK gel (water-swollen KONJAK powder produced by adding about 30pts. of water to 1pt. of KONJAK powder), (B) carrageenan and (C) hydrolyzed gelatin (produced by adding about 0.05pts. of a proteinase to about 70pts. of water, slowly adding 30pts. of dried gelatin powder to the obtained liquid, vigorously stirring the mixture, heat-treating at <=45 deg.C and inactivating the product). The substrate is mixed with a cosmetic pack material and the obtained mixture is heat-treated, poured into a thin container, solidified, dried and rolled to obtain the objective cosmetic pack. The pack is a peel-off type one which can be applied to the skin simply by pasting to the skin without using the labor of coating, etc.
Severe trauma is an intractable problem in healthcare. Patients have a widespread immune system response that is complex and vital to survival. Excessive inflammatory response is the main cause of poor prognosis and poor therapeutic effect of medications in trauma patients. Cytokines are signaling proteins that play critical roles in the body's response to injuries, which could amplify or suppress immune responses. Studies have demonstrated that cytokines are closely related to the severity of injuries and prognosis of trauma patients and help present cytokine-based diagnosis and treatment plans for trauma patients. In this review, we introduce the pathophysiological mechanisms of a traumatic inflammatory response and the role of cytokines in trauma patients. Furthermore, we discuss the potential of cytokine-based diagnosis and therapy for post-traumatic inflammatory response, although further clarification to elucidate the underlying mechanisms of cytokines following trauma is warranted.
This study´s objective was to identify the effectiveness of nursing orientation for the reduction of anxiety and stress of patients that was waiting cardiac catheterization. Method. This is a randomized clinical trial. The sample consisted of patients that was waiting cardiac catheterization who were divided into two groups: intervention group (patients who received nursing orientation with a validated guidance manual about this procedure) and control group (patients who received the routine nursing orientation). The subjects were consulted about the desire to participate, and those who agreed, signed the consent form. The patients were randomized to one of two groups (control or intervention), according to the sequence determined by the Random System. Randomization was carried out by a teacher who did not participate of any phase of this study. After randomization, the patients were instructed how to fill out the instruments. The primary end points were the anxiety and stress, which was evaluated in two moments (before and after the nursing orientation). The State Anxiety Inventory (STAI-state) was used to assess anxiety and the Perceived Stress Scale (PSS-10) was used to assess stress. Subsequent to this first evaluation, the patients, both in the control group and in the intervention group, received the intervention by another profissional. After the patients were evaluated about anxiety and stress. Prior to the collection, the research project was submitted to the Research Ethics Committee and the data was collected after its approval.
Freezing of gait (FoG) is a common disabling symptom of Parkinson's disease (PD). It is clinically characterized by sudden and transient walking interruptions for specific human body parts, and it presents the localization in time and space. Due to the difficulty in extracting global fine-grained features from lengthy videos, developing an automated five-point FoG scoring system is quite challenging. Therefore, we propose a novel video-based automated five-classification FoG assessment method with a causality-enhanced multiple-instance-learning graph convolutional network (GCN). This method involves developing a temporal segmentation GCN to segment each video into three motion stages for stage-level feature modeling, followed by a multiple-instance-learning framework to divide each stage into short clips for instance-level feature extraction. Subsequently, an uncertainty-driven multiple-instance-learning GCN is developed to capture spatial and temporal fine-grained features through GCN scheme and uncertainty learning, respectively, for acquiring global representations. Finally, a causality-enhanced graph generation strategy is proposed to exploit causal inference for mining and enhancing human structures causally related to clinical assessment, thereby extracting spatial causal features. Extensive experimental results demonstrate the excellent performance of the proposed method on five-classification FoG assessment with an accuracy of 62.72% and an acceptable accuracy of 91.32%, which is confirmed by independent testing. Additionally, it enables temporal and spatial localization of FoG events to a certain extent, facilitating reasonable clinical interpretations. In conclusion, our method provides a valuable tool for automated FoG assessment in PD, and the proposed causality-related component exhibits promising potential for extension to other general and medical fine-grained action recognition tasks.
Breathing exercises can be applied specifically to different segments of the lungs, increasing collateral ventilation and helping mobilize secretions. Chronic respiratory diseases, rib cage deformities, neuromuscular diseases that cause breathing problems, lung transplant or lung surgery patients in the pre-operative and post-operative period, cancer patients, heart failure patients and cardiovascular surgery patients, and those whose quality of life is impaired due to shortness of breath. People are known to be groups that benefit from breathing exercises. Breathing exercises have been shown to be effective in preserving respiratory function and preventing or reducing respiratory complications in all of these conditions. It has been reported that respiratory muscle training applied within the scope of pre- and post-operative cardiac rehabilitation programs is beneficial in increasing respiratory functions and reducing the risk of postoperative complications and length of stay. Respiratory muscle training is known to have many potential beneficial effects on patients undergoing cardiac surgery. Different methods and devices are used to improve and develop the functions of inspiratory and expiratory muscles, and each training method and device has differences. For this reason, the respiratory exercise device to be developed is aimed to be a device that can be shaped according to the desired purpose, has visual feedback, and can combine multiple respiratory muscle training methods. The device is thought to play an active role in rehabilitating complications such as lung ventilation and respiratory muscle weakness, which are frequently affected in patients after major surgery such as cardiac surgery. Therefore, it is thought that examining the clinical effects of using a personalized breathing exercise device on respiratory functions, respiratory muscle strength, and functional capacity in individuals who have undergone cardiac surgery will contribute to the literature.
This is a one-minute, ready-to-use fluoride treatment rinse for in-office patient use. Remove cap from bottle and insert enclosed pump into bottle and tighten. Pump ½ oz into a cup. Instruct patient to thoroughly rinse the entire amount around and between teeth for one minute, then spit-out rinse. Repeat the procedure to ensure maximum benefit. Instruct patient not to eat or drink for at least 30 minutes.
A multi-compartment capsule including a primary capsule and a secondary capsule selectively positionable within an internal periphery of the primary capsule. The secondary capsule includes a base, a corresponding cap and one or more receiving chambers. Each of the receiving chambers of the secondary capsule may be formed having an internal periphery sufficient for receiving at least one active ingredient or medicament (e.g., pharmaceutical, biotechnical, nutraceutical, vitamin, dietary supplement, mineral or combination thereof) therein. Similarly, the primary capsule may be formed having a base, a corresponding cap and one or more receiving chambers. The receiving chambers of the primary capsule are preferably formed having an internal periphery sufficient for receiving the secondary capsule, together with one or more active ingredients or medicaments (e.g., pharmaceutical, biotechnical, nutraceutical, vitamin, dietary supplement, mineral or combination thereof) therein. The active ingredient(s) in the primary capsule having a physical state (i.e., solid, liquid, gas or dispersion) different from the physical state of the active ingredient(s) in the secondary capsule. In addition, the component parts of the multi-compartment capsule may include various time-release coatings to facilitate the release and ultimately the absorption of the active ingredients introduced in the different receiving chambers to release at different release rates. Moreover, the cap of the primary capsule may be configured in such a manner or a filling material may be introduced into the internal periphery of the cap which generally eliminates or substantially reduces any potential dead space volume within the primary capsule, thereby functionally negating the opportunity for reaction between an air bubble and one or more of the active ingredients introduced into the primary capsule in an effort to improve stability of the capsular ingredient(s).
ENTRESTO may cause angioedema [see Adverse Reactions (6.1)]. If angioedema occurs, discontinue ENTRESTO immediately, provide appropriate therapy, and monitor for airway compromise. ENTRESTO must not be re-administered. In cases of confirmed angioedema where swelling has been confined to the face and lips, the condition has generally resolved without treatment, although antihistamines have been useful in relieving symptoms.

Angioedema associated with laryngeal edema may be fatal. Where there is involvement of the tongue, glottis or larynx, likely to cause airway obstruction, administer appropriate therapy, e.g., subcutaneous epinephrine/adrenaline solution 1:1000 (0.3 mL to 0.5 mL) and take measures necessary to ensure maintenance of a patent airway.

ENTRESTO has been associated with a higher rate of angioedema in Black than in non-Black patients.

Patients with a prior history of angioedema may be at increased risk of angioedema with ENTRESTO [see Adverse Reactions (6.1)]. ENTRESTO must not be used in patients with a known history of angioedema related to previous ACE inhibitor or ARB therapy [see Contraindications (4)]. ENTRESTO should not be used in patients with hereditary angioedema.
First group will include 20 young adults with no history of falls or fear of falling. They will complete both interventions: Balance Training with Fall-Arrest Harness and Balance Training with Adjustable Harness.
The present invention discloses a method for producing asparagus saponin, which comprises the steps of pulverization of raw materials, the addition of 2 to 10 times of ethanol, heating from 50 to 100DEG. C, and extraction for 1 to 10 hours. A crude product of fine powder is obtained by filtration, condensation, addition of precipitating agents, and centrifugal cooling and drying, and the crude product is added with macroporous adsorptive resin for separating and purifying. Accordingly, the refined product of the asparagus saponin is obtained. The present invention has wide sources of raw materials and simple and convenient production process. The asparagus saponin has the efficiency of preventing cancers, resisting cancers, reducing blood lipid, reducing cholesterol, etc. The present invention can be used for preparing anti-cancer health care medicine and health care food.
The invention discloses a pioglitazone hydrochloride solid dispersoid and a medicinal compounds thereof as well as preparation methods and applications thereof. The pioglitazone hydrochloride solid dispersoid contains pioglitazone hydrochloride and PEG6000, with the weight ratio of 1:1. 5-9. The preparation method of the pioglitazone hydrochloride solid dispersoid comprises the following steps: A1. heating the PEG6000 to 60-80 DEG C, so as to enable the PEG6000 to be in a liquid state; A2. under the condition of constantly stirring the solution, adding the pioglitazone hydrochloride with proportional amount, stirring and dispersing for 20-40 minutes; and A3. quickly pouring a mixture on a metal panel with fast heat conduction to form a thin solid layer, immediately placing the thin solid layer in an environment with temperature below -20 DEG C, quenching for 50-70 minutes, taking out, smashing and screening with a 100-mesh sieve. The invention has the beneficial effects that the solid dispersoid can greatly improve the dissolution rate of the pioglitazone hydrochloride in a dissolution medium, so as to increase bioavailability. A solid dispersing agent can be further made into the medicinal compounds in forms of tablets and capsules.
No treatment for 6 months, then participants were treated with JUVÉDERM® VOLUMA® XC Injectable Gel, volume determined by the investigator (up to 12 mLs). Participants were eligible for re-treatment if applicable.
INTRODUCTION: Endoscopic approaches for skull base pathologies are increasingly being performed, and the subsequent complications, especially in the long term, have also been partially clarified. However, there is no information on the effects of endoscopic endonasal skull base surgeries (EESBS) in children on odor and facial development in parallel with long-term development. We conducted this study to investigate postoperative olfactory function and facial development in pediatric patients who underwent skull base surgery using the endoscopic endonasal method.
METHODS: We evaluated the smell test, sinonasal symptoms, and facial development of pediatric patients who underwent endoscopic endonasal skull base surgery after long-term follow-up. Odor was evaluated using the "Sniffin' Sticks" test kit, which assessed the T (odor threshold), D (odor discrimination), and I (odor identification) parameters. Sinonasal symptoms were evaluated using the SNOT-22 (sinus-nose outcome test) questionnaire. SNA (sella-nasion-A point), SNB (sella-nasion-B point), and ANB (A point-nasion-B point) angles were calculated from maxillofacial tomography and magnetic resonance imaging) to evaluate facial development. Data were compared with those of the healthy control group.
RESULTS: We included 30 patients comprising 19 (63.3%) boys and 11 (36.7%) girls, with no age difference between case and control groups. The mean follow-up period was 7 years. Odor test data, cephalometric measurements, and SNOT-22 analysis results showed no statistically significant differences between the two groups.
CONCLUSION: To our knowledge, this is a comprehensive study with the longest follow-up period in terms of evaluation of facial development after EESBS in children to analyze odor using the Sniffin' Sticks test kit and the quality of life using SNOT-22. Olfactory function, facial development, and quality of life remained unaffected after long-term follow-up after EESBS  in children. Although this surgical approach is minimally invasive, we recommend considering the possibility of complications, and the procedure should be performed by an experienced surgical team with adequate equipment.
The 3-day voiding diary group is as the experimental group in which several centers use the 3-day voiding diary by cluster randomization. The 3-day voiding diary is a medical record which need participants to fill in a table about urine volume for 2 days and 3 nights.
FIELD: medicine, biochemistry. SUBSTANCE: 10 kg frozen seal heart are thawed, washed with water, fat and ligaments are removed, and tissue is minced. Mince is extracted with trichloroacetic acid solution (at pH 3.8-4.1) for 2 h, extract is separated by filtration, and NaOH is added up to pH 6.0. Proteins are precipitated with crystalline ammonium sulfate. After filtration crystalline ammonium sulfate is added to filtrate obtained. After settling the solution is filtered, and 20% solution of trichloroacetic acid is added to filtrate. Precipitate is separated by centrifugation, treated with ammonium sulfate solution and centrifuged again. Precipitate of cytochrome c is dissolved in distilled water and frozen at (-10)-(-15) C following by thawing and filtration. Concentrated solution is dialyzed, prepared solution is heated and filtered. Filtrate is diluted with saline solution, filtered under sterile conditions, bottled and lyophilized. EFFECT: simplified method, enhanced yield of the end product. 2 tbl
BACKGROUND: Hepatocellular carcinoma (HCC) accounts for approximately 90% of liver cancer cases. Sorafenib, the first drug to demonstrate survival benefits for advanced HCC, was validated through the SHARP randomized clinical trial (RCT). While RCTs are essential for assessing new therapies, real-world studies provide additional insights into their effectiveness in routine clinical practice. This study aimed to evaluate sorafenib's real-world effectiveness by analyzing overall survival (OS) and the time to radiological and symptomatic progression.
METHODS: Data from 368 patients treated with sorafenib at a Brazilian Cancer Center between 2009 and 2020 were retrospectively reviewed.
RESULTS: The median OS was 9.6 months, and the time to radiological progression was 5.3 months, similar to the SHARP trial. However, the time to symptomatic progression was shorter (2.3 months) than the SHARP study (4.1 months). In terms of safety, 27.4% of patients presented clinically relevant toxicities, and 24.5% needed to discontinue treatment due to toxicity.
CONCLUSIONS: Overall, sorafenib demonstrated effectiveness in the studied population, with OS and radiological progression times comparable to SHARP study results. The difference in symptomatic progression may be due to the study's retrospective nature and limitations.
One in three women will experience pelvic floor disorders in her lifetime and nearly 60 percent of postmenopausal women are affected by vaginal dryness. Conservative management is recommended as first line treatment for pelvic organ prolapse and stress urinary incontinence. Also, vaginal estrogens are often prescribed for symptomatic vaginal atrophy. Lasers have been used in cosmetic industry for connective tissue remodeling and repair of skin. Their use in the last decade for treating genitourinary symptoms of menopause, pelvic organ prolapse and stress urinary incontinence has gained popularity but there is lack of robust evidence to support its use in routine practice. The European Board and College of Obstetrics and Gynaecology calls for high quality evidence with patient related outcome measures before adopting to routine clinical practice.
Repetitive transcranial magnetic stimulation (rTMS) has become a safe and efficacious treatment for patients with treatment-resistant depression (Mutz et al., 2019). Consequently, several countries including Australia, Brazil, Canada, Israel and the United States have approved rTMS as second-line treatment for major depressive disorder (MDD), while others have included rTMS in their guidelines for good clinical practice (e.g. Finland, Germany and Serbia). Historically, rTMS was conceptualized as a "soft" alternative to electroconvulsive therapy. Therefore, most studies to date primarily recruited patients with relatively high degrees of treatment-resistance (\> two failed treatment attempts) and there is a lack of trials investigating rTMS as a first or second line treatment. This finding is contrasted by the fact that on the most stable predictors of response to rTMS is low-treatment resistance.

Therefore, this trial aims to compare the antidepressant efficacy of 20 pharmaco-naïve patients with 20 treatment-resistant patients diagnosed with major depressive disorder. In this open label trial, patients will receive four weeks high-frequency left-sided theta burst TMS (lDLFPC). The target will be located by neuronavigation to the target ascertained by Fox et al.
Participants received two treatment session at least 2 weeks apart. Investigator applied a thin layer of vehicle cream to each lesion during treatment. At 30 minutes after cream application, participants went outside in daylight for 2 hours (DL-PDT). After this time, the cream was removed by investigative site personnel by washing the skin with gentle skin cleanser.
A once daily dosage of Insulin detemir (Levemir®) 100 U/mL 3 mL FlexPen® for subcutaneous administration was selected for this trial.During the treatment period insulin detemir was adjusted by the subject themselves (self-titration). Self-titration was performed every 3 days based on the lowest of three previous consecutive pre-breakfast SMPG values.Based on this glucose value, self-adjustment of insulin detemir dose was done. Metformin and Sulfonlylurea were allowed as OADs. For SMPG values, the following insulin detemir dose adjustments were done : \>6.1 mmol/L (\>110 mg/dL) +3U insulin detemir, 4.4-6.1 mmol/L (80-100 mg/dL) No adjustment in insulin detemir, \< 4.4 mmol/L (\<80 mg/dL) -3U insulin detemir.